Substrate Ablation of Ventricular Tachycardia: Late Potentials, Scar Dechanneling, Local Abnormal Ventricular Activities, Core Isolation, and Homogenization
- 1 March 2017
- journal article
- review article
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 9 (1) , 81-91
Abstract
No abstract availableKeywords
Funding Information
- Janssen Pharmaceutica
- St. Jude Medical
- Biotronik
- Biosense Webster
- Pfizer
- Medtronic
- Boston Scientific Corporation
This publication has 34 references indexed in Scilit:
- Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic DrugsNew England Journal of Medicine, 2016
- Substrate mapping for unstable ventricular tachycardiaHeart Rhythm, 2016
- Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group studyHeart Rhythm, 2015
- The role of catheter ablation in the management of ventricular tachycardiaEuropean Heart Journal, 2015
- Catheter ablation of ventricular tachycardia in ischaemic and non-ischaemic cardiomyopathy: where are we today? A clinical reviewEuropean Heart Journal, 2012
- Venice Chart International Consensus Document on Ventricular Tachycardia/Ventricular Fibrillation AblationJournal of Cardiovascular Electrophysiology, 2010
- Prognostic Importance of Defibrillator Shocks in Patients with Heart FailureNew England Journal of Medicine, 2008
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart FailureNew England Journal of Medicine, 2005
- Sudden Death Due to Cardiac ArrhythmiasNew England Journal of Medicine, 2001
- Meta-analysis of the implantable cardioverter defibrillator secondary prevention trialsEuropean Heart Journal, 2000